Q1 Earnings Forecast for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, February 10th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of ($1.48) per share for the quarter. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $9.90 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the previous year, the firm earned ($1.32) EPS.

Several other research firms also recently commented on AXSM. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a report on Thursday, December 12th. Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a report on Monday. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Mizuho upped their price objective on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $147.13.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $131.68 on Wednesday. The company’s 50-day moving average is $96.55 and its 200 day moving average is $92.67. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The company has a market capitalization of $6.38 billion, a P/E ratio of -20.17 and a beta of 1.05. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $134.18.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its position in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after purchasing an additional 185,951 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock worth $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after purchasing an additional 8,125 shares during the last quarter. Invesco Ltd. increased its position in shares of Axsome Therapeutics by 10.8% in the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock worth $58,589,000 after purchasing an additional 67,285 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $34,100,000. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.